BioCentury | Jun 6, 2020
Translation in Brief

Engineered bacteria for targeted bacterial killing; plus Cas12a base editors, base editing to restore hearing and more

Targeted delivery of antibacterial toxins  University of Washington researchers have co-opted a bacterial secretion system to enable killing of select bacterial species. They d escribed in Cell Host & Microbe how they programmed bacteria with...
BioCentury | May 28, 2020
Distillery Therapeutics

Increasing WWTR1 degradation for NASH

DISEASE CATEGORY: Hepatic INDICATION: Non-alcoholic steatohepatitis (NASH) Promoting proteasomal degradation of the transcription factor WWTR1 by inhibiting a cholesterol-associated signaling pathway could treat NASH. The cholesterol trafficking proteins GRAMD1B and GRAMD1C activate SAC, which in...
BioCentury | May 9, 2020
Deals

Columbia’s peptide nucleic acid technology draws Fortress into rare discovery deal

Fortress Biotech broke from its mold of licensing clinical assets to access a Columbia University peptide nucleic acid technology in discovery. The new technology will be housed in Fortress’ newly formed Oncogenuity Inc. subsidiary. The...
BioCentury | Apr 25, 2020
Targets & Mechanisms

Trends to surf for at AACR 2020

While the abstracts for this year’s virtual AACR meeting won’t be available until Monday -- and most data won’t be presented until June -- key session titles, combined with an analysis of recent trends in...
BioCentury | Apr 9, 2020
Tools & Techniques

NCI takes lead on serological test validation as cancer center joins COVID-19 fight

Deploying its HPV serology testing lab to validate COVID-19 assays is one of three ways NIH’s National Cancer Institute is retooling cancer research activities to take on the pandemic. In a virtual advisory committee meeting...
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally signal that an IPO is in the offing, President and CEO Barbara Weber thinks the wealth of targets that...
BioCentury | Apr 1, 2020
Distillery Therapeutics

Metabolite scavengers to resensitize K-Ras-mutant colorectal cancer to Erbitux

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer Scavengers of the glycolysis metabolite methylglyoxal could resensitize K-Ras-mutant colorectal cancer to Erbitux cetuximab. In patients, levels of methylglyoxal adducts were higher in tumors with K-Ras G12V mutations than...
BioCentury | Feb 28, 2020
Finance

Verastem raises $100M, plots path forward with targeted cancer combo

Based on an early peek at clinical data, an investor syndicate is endorsing Verastem’s strategic realignment behind a pipeline combo in a targeted cancer indication. The group is pouring $100 million into the company at...
BioCentury | Feb 28, 2020
Emerging Company Profile

Lava: better safety for bispecifics with γδ T cell engagement

Lava’s bispecific mAbs targeting γδ T cells could match the potency of other T cell engaging technologies while offering a larger therapeutic window. The company joins a growing group of biotechs focused on γδ T...
BioCentury | Feb 27, 2020
Product Development

Amgen banks on speed to maintain edge in two hot cancer spaces

Amgen has a first-mover advantage in two of the hottest areas of cancer R&D -- K-Ras and bispecific antibodies. To stay ahead, it’s banking on a combination of rapid clinical development and moving to earlier...
Items per page:
1 - 10 of 1163